Phio Pharmaceuticals Corp. — Director's Dealing 2024

Feb 27, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phio Pharmaceuticals Corp. (PHIO)
CIK: 0001533040
Period of Report: 2024-02-26

Reporting Person: Bitterman Robert J (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-26	Common stock, $0.0001 par value	P	2500	$0.91	Acquired	18990	Direct

Footnotes

F1: Includes shares of common stock underlying unvested restricted stock units.